Protagonist Therapeutics Files 8-K on Financials
Ticker: PTGX · Form: 8-K · Filed: May 7, 2024 · CIK: 1377121
Sentiment: neutral
Topics: financial-reporting, operations-update
TL;DR
Protagonist Therapeutics filed an 8-K on May 7th, updating on financials and operations.
AI Summary
Protagonist Therapeutics, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.
Why It Matters
This 8-K filing indicates that Protagonist Therapeutics is providing updates on its financial condition and results of operations, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- May 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37852 (identifier) — Commission File Number
- 98-0505495 (identifier) — IRS Employer Identification No.
- 7707 Gateway Blvd., Suite 140 (address) — Business and mailing address
- Newark (location) — City of business address
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific figures or detailed updates are not provided in the excerpt.
When was the earliest event reported in this Form 8-K?
The earliest event reported is dated May 7, 2024.
What is the Commission File Number for Protagonist Therapeutics, Inc.?
The Commission File Number is 001-37852.
In which state was Protagonist Therapeutics, Inc. incorporated?
Protagonist Therapeutics, Inc. was incorporated in Delaware.
What is the business address of Protagonist Therapeutics, Inc.?
The business address is 7707 Gateway Blvd., Suite 140, Newark, CA 94560-1160.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-05-07 16:29:02
Key Financial Figures
- $0.00001 — h registered Common Stock, par value $0.00001 PTGX The Nasdaq Stock Market LLC
Filing Documents
- tm2413671d1_8k.htm (8-K) — 27KB
- tm2413671d1_ex99-1.htm (EX-99.1) — 64KB
- tm2413671d1_ex99-1img001.jpg (GRAPHIC) — 16KB
- 0001104659-24-058036.txt ( ) — 294KB
- ptgx-20240507.xsd (EX-101.SCH) — 3KB
- ptgx-20240507_lab.xml (EX-101.LAB) — 33KB
- ptgx-20240507_pre.xml (EX-101.PRE) — 22KB
- tm2413671d1_8k_htm.xml (XML) — 4KB
02. Results of Operations
Item 2.02. Results of Operations and Financial Condition. On May 7, 2024, Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2024. A copy of the press release titled "Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update" is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated May 7, 2024, titled "Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagonist Therapeutics, Inc. Dated: May 7, 2024 By: /s/ Asif Ali Asif Ali Chief Financial Officer